Guidelines for the management of chronic kidney disease

Adeera Levin; Brenda Hemmelgarn; Bruce Culleton; Sheldon Tobe; Philip McFarlane; Marcel Ruzicka; Kevin Burns; Braden Manns; Colin White; Francoise Madore; Louise Moist; Scott Klarenbach; Brendan Barrett; Robert Foley; Kailash Jindal; Peter Senior; Neesh Pannu; Sabin Shurraw; Ayub Akbari; Adam Cohn; Martina Reslerova; Vinay Deved; David Mendelssohn; Gihad Nesrallah; Joanne Kappel; Marcello Tonelli

doi:10.1503/cmaj.080351

Guidelines for the management of chronic kidney disease

Adeera Levin, Brenda Hemmelgarn, Bruce Culleton, Sheldon Tobe, Philip McFarlane, Marcel Ruzicka, Kevin Burns, Braden Manns, Colin White, Francoise Madore, Louise Moist, Scott Klarenbach, Brendan Barrett, Robert Foley, Kailash Jindal, Peter Senior, Neesh Pannu, Sabin Shurraw, Ayub Akbari, Adam CohnMartina Reslerova, Vinay Deved, David Mendelssohn, Gihad Nesrallah, Joanne Kappel, Marcello Tonelli

Medicine - Renal and Hypertension Division

Research output: Contribution to journal › Review article › peer-review

278 Scopus citations

Original language	English (US)
Pages (from-to)	1154-1162
Number of pages	9
Journal	Canadian Medical Association Journal
Volume	179
Issue number	11
DOIs	https://doi.org/10.1503/cmaj.080351
State	Published - Nov 18 2008

Bibliographical note

Funding Information:
Philip McFarlane has been a consultant to or an advisory board member of Ortho Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Pfizer, Novartis, AstraZeneca, Fresenius, Boehringer Ingelheim, Roche and Schering-Plough. He has received honoraria for presentations from Ortho-Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Novartis, Abbott and Merck. Philip McFarlane has participated in or received research grant funding from Sanofi-Aventis, GlaxoSmithKline, Biovail, Boehringer Ingelheim, AstraZeneca, Ortho Biotech and Amgen.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1503/cmaj.080351

OpenUrl availability

Full text

Cite this

Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., Burns, K., Manns, B., White, C., Madore, F., Moist, L., Klarenbach, S., Barrett, B., Foley, R., Jindal, K., Senior, P., Pannu, N., Shurraw, S., Akbari, A., ... Tonelli, M. (2008). Guidelines for the management of chronic kidney disease. Canadian Medical Association Journal, 179(11), 1154-1162. https://doi.org/10.1503/cmaj.080351

Levin, A, Hemmelgarn, B, Culleton, B, Tobe, S, McFarlane, P, Ruzicka, M, Burns, K, Manns, B, White, C, Madore, F, Moist, L, Klarenbach, S, Barrett, B, Foley, R, Jindal, K, Senior, P, Pannu, N, Shurraw, S, Akbari, A, Cohn, A, Reslerova, M, Deved, V, Mendelssohn, D, Nesrallah, G, Kappel, J & Tonelli, M 2008, 'Guidelines for the management of chronic kidney disease', Canadian Medical Association Journal, vol. 179, no. 11, pp. 1154-1162. https://doi.org/10.1503/cmaj.080351

@article{715fb0ea34c346dc845ac04eedacf6ae,

title = "Guidelines for the management of chronic kidney disease",

author = "Adeera Levin and Brenda Hemmelgarn and Bruce Culleton and Sheldon Tobe and Philip McFarlane and Marcel Ruzicka and Kevin Burns and Braden Manns and Colin White and Francoise Madore and Louise Moist and Scott Klarenbach and Brendan Barrett and Robert Foley and Kailash Jindal and Peter Senior and Neesh Pannu and Sabin Shurraw and Ayub Akbari and Adam Cohn and Martina Reslerova and Vinay Deved and David Mendelssohn and Gihad Nesrallah and Joanne Kappel and Marcello Tonelli",

note = "Funding Information: Philip McFarlane has been a consultant to or an advisory board member of Ortho Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Pfizer, Novartis, AstraZeneca, Fresenius, Boehringer Ingelheim, Roche and Schering-Plough. He has received honoraria for presentations from Ortho-Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Novartis, Abbott and Merck. Philip McFarlane has participated in or received research grant funding from Sanofi-Aventis, GlaxoSmithKline, Biovail, Boehringer Ingelheim, AstraZeneca, Ortho Biotech and Amgen. ",

year = "2008",

month = nov,

day = "18",

doi = "10.1503/cmaj.080351",

language = "English (US)",

volume = "179",

pages = "1154--1162",

journal = "Canadian Medical Association Journal",

issn = "0820-3946",

publisher = "Canadian Medical Association",

number = "11",

}

TY - JOUR

T1 - Guidelines for the management of chronic kidney disease

AU - Levin, Adeera

AU - Hemmelgarn, Brenda

AU - Culleton, Bruce

AU - Tobe, Sheldon

AU - McFarlane, Philip

AU - Ruzicka, Marcel

AU - Burns, Kevin

AU - Manns, Braden

AU - White, Colin

AU - Madore, Francoise

AU - Moist, Louise

AU - Klarenbach, Scott

AU - Barrett, Brendan

AU - Foley, Robert

AU - Jindal, Kailash

AU - Senior, Peter

AU - Pannu, Neesh

AU - Shurraw, Sabin

AU - Akbari, Ayub

AU - Cohn, Adam

AU - Reslerova, Martina

AU - Deved, Vinay

AU - Mendelssohn, David

AU - Nesrallah, Gihad

AU - Kappel, Joanne

AU - Tonelli, Marcello

N1 - Funding Information: Philip McFarlane has been a consultant to or an advisory board member of Ortho Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Pfizer, Novartis, AstraZeneca, Fresenius, Boehringer Ingelheim, Roche and Schering-Plough. He has received honoraria for presentations from Ortho-Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Novartis, Abbott and Merck. Philip McFarlane has participated in or received research grant funding from Sanofi-Aventis, GlaxoSmithKline, Biovail, Boehringer Ingelheim, AstraZeneca, Ortho Biotech and Amgen.

PY - 2008/11/18

Y1 - 2008/11/18

UR - http://www.scopus.com/inward/record.url?scp=56649086676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649086676&partnerID=8YFLogxK

U2 - 10.1503/cmaj.080351

DO - 10.1503/cmaj.080351

M3 - Review article

C2 - 19015566

AN - SCOPUS:56649086676

SN - 0820-3946

VL - 179

SP - 1154

EP - 1162

JO - Canadian Medical Association Journal

JF - Canadian Medical Association Journal

IS - 11

ER -

Guidelines for the management of chronic kidney disease

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Cite this